January 2003
Worldwide Biotech;Jan2003, Vol. 15 Issue 1, p4
Trade Publication
Deals with the recommendation given by the European Union's Committee for Proprietary Medicinal Products on granting Marketing Authorisation for Hepsera, a treatment for chronic hepatitis B.


Related Articles

  • EU Rules Evolve while Clinical Trials Directive Simmers. O'Donnell, Peter // Applied Clinical Trials;Mar2001, Vol. 10 Issue 3, p32 

    Reports on the unfinalized text of the clinical trials directive of the European Union. Changes within the Committee for Proprietary Medical Products (CPMP); Strategy for coping with missing data; Issuance of guidance for postmenopausal osteoporosis.

  • Prescribing info for ESAs updated in the US and Europe.  // Reactions Weekly;3/15/2008, Issue 1193, p3 

    The article reports on the approval of an updated safety information for erythropoiesis-stimulating agents (ESAs) by the U.S. Food and Drug Administration (FDA), and the finalisation of amendments to the prescribing information for Aranesp, a synthetic erythropoietin, by the European Union...

  • PharmaMar and Zeltia to appeal against negative Yondelis opinion.  // PharmaWatch: Biotechnology;September 2003, Vol. 2 Issue 9, p16 

    Reports on the appeal made by PharmaMar SA and Zeltia SA concerning the negative opinion expressed by the European Union's Committee for Proprietary Medicinal Products on the companies' investigational treatment for advanced soft tissue sarcoma. Name of the drug promoted by both companies;...

  • Roche given additional recommendation for Bondronat.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p8 

    Reports that the European Union's Committee for Proprietary Medicinal Products has issued a positive opinion for the use of Roche's Bondronat in the prevention of skeletal events, such as pathological fractures, bone complications requiring radiotherapy or surgery, in patients with breast cancer...

  • CPMP gives positive opinion on Emtriva.  // PharmaWatch: Biotechnology;September 2003, Vol. 2 Issue 9, p13 

    Reports on the recommendation from the European Union's Committee for Proprietary Medicinal Products concerning the HIV drug developed by Gilead Sciences Inc. Name of the drug; Recommendation granting marketing authorization for the product; Date expected for the European Commission to act on...

  • FDA and CPMP Rulings on Subgroup Analyses. Maggioni, Aldo P.; Darne, Bernadette; Atar, Dan; Abadie, Eric; Pitt, Bertram; Zannad, Faiez // Cardiology;2007, Vol. 107 Issue 2, p97 

    The extent to which subgroup analyses should affect the interpretation and conclusions in a trial report is a contentious matter, and guidelines regarding this issue have been established by the US Food and Drug Administration (FDA) and the EU Committee for Proprietary Medicinal Products (CPMP)....

  • Transient hypothyroidism in a child treated with... Abdul-Jabbar, M.A.; Ehrlich, R.M. // Clinical Pediatrics;Dec1995, Vol. 34 Issue 12, p663 

    Reports that a 13 year old boy was found positive for hepatitis B after his mother and father were both positive. Description of disease; Statistics.

  • Comment on: Epidemiology of Hepatitis B Virus Infection in Hamadan, Western Iran. Kabir, Ali; Alavian, Seyed Moayed; Poorolajal, Jalal // Journal of Research in Health Sciences;Jun2011, Vol. 11 Issue 2, p121 

    A letter to the editor and a reply are presented in response to the article "Hepatitis B and C Infections in Hamadan Province during 2004-2009," by Jalal Poorolajal and colleagues in the 2011 issue.

  • Guarding against Hepatitis B.  // NEA Today;Jan97, Vol. 15 Issue 5, p23 

    Presents information on the disease Hepatitis B. Information on the origin of the disease and how it can be transmitted; How to prevent Hepatitis B; How students can be immunized through school programs; Who are at risk for the disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics